TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pro-Dex ( (PDEX) ) has issued an update.
On November 20, 2025, Pro-Dex, Inc.’s Compensation Committee approved the grant of restricted common shares to non-employee directors and select employees, including 1,000 shares to CFO Alisha K. Charlton, under its 2016 Equity Incentive Plan. Additionally, a discretionary cash bonus equivalent to 1,000 shares was awarded to CEO Richard L. Van Kirk. The same day, the company held its 2025 Annual Meeting of Shareholders, where all board candidates were elected, Baker Tilly US, LLP was ratified as the independent auditor, executive compensation was approved, and the 2016 Equity Incentive Plan was extended by ten years.
The most recent analyst rating on (PDEX) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Pro-Dex stock, see the PDEX Stock Forecast page.
Spark’s Take on PDEX Stock
According to Spark, TipRanks’ AI Analyst, PDEX is a Neutral.
Pro-Dex’s strong valuation and financial performance are the primary strengths, with an attractive P/E ratio and robust revenue growth. However, technical indicators suggest a bearish trend, and cash flow challenges need attention. The absence of dividend yield and earnings call data limits further insights.
To see Spark’s full report on PDEX stock, click here.
More about Pro-Dex
Pro-Dex, Inc. operates in the industry of manufacturing and distributing precision medical devices and components. The company focuses on providing innovative solutions and products for the medical, dental, and industrial markets.
Average Trading Volume: 52,092
Technical Sentiment Signal: Hold
Current Market Cap: $94.3M
For detailed information about PDEX stock, go to TipRanks’ Stock Analysis page.